Use Paracetamol to treat OA pain, says global expert

November 07, 1999

November 8, 1999 - Paracetamol, in doses of up to 4000 mg/day, is still the first-line drug of choice for the management of the pain of osteoarthritis (OA), despite the recent emergence of new symptomatic treatments, according to Professor Kenneth Brandt, Head of the Rheumatology Division at Indiana University School of Medicine, USA. This was the general consensus reached by global OA experts at an International Symposium held today in Sydney, Australia.

Delegates at the 'Clinical Consensus - An International Update on Paracetamol' symposium in Sydney Australia, heard Professor Brandt outline the rationale behind the choice of paracetamol.

"In the past, treatment of OA was most often initiated with the prescription of non-steroidal anti-inflammatory drugs (NSAIDs)," said Professor Brandt. "However, evidence suggests that these drugs offer no advantage over simple analgesics, such as paracetamol in OA. Furthermore, NSAID-related adverse gastrointestinal (GI) effects are now recognised as a serious problem." In the US each year among people over the age of 65, there are 40,000 hospitalisations and 3000 deaths attributable to NSAID associated GI catastrophes.

Professor Brandt summarised the evidence that led to the recommendation of paracetamol as the first-line drug of choice in OA management:"In part because of their GI toxicity, which is dose-dependent, it is suggested that NSAIDs be used in the lowest possible dose for the shortest possible time. Clinical studies have shown that low analgesic doses of NSAIDs are often as effective as higher anti-inflammatory doses, which raises a question over the wisdom of placing patients on treatments which increase their risk of GI events without demonstrable superior efficacy. Furthermore, in clinical practice, only 15% of patients being treated for OA pain with an NSAID are still on the same NSAID at the end of the year, as a result of lack of efficacy, GI side effects or other events," continued Professor Brandt. Patient satisfaction with chronic NSAID use in OA is simply not very high.

"In OA, it has been shown that patients who take a simple analgesic, like paracetamol, as an adjunct to a comprehensive programme of non-pharmacologic measures, like weight-loss (if the patient is obese), exercise to strengthen the muscles around the joint and application of joint-protection principles, can often manage their condition adequately, without the need for additional drug-treatment. Indeed, as many as 50% of OA patients can achieve adequate symptomatic relief with these measures," he said. This recommendation reflects global medical opinion and guidelines on OA management from a number of professional bodies around the world including the American College of Rheumatology.1 2

The recent emergence of newer 'GI-tolerant' NSAIDs that specifically inhibit cyclo-oxygenase 2 (COX 2) has particularly focused attention on the GI toxicity associated with conventional NSAIDs. However, the place of these new drugs in OA management is not yet fully established, said Professor Brandt: "The COX 2s are clearly safer for the stomach than conventional NSAIDs in endoscopy studies, but it has yet to be shown that they will be associated with a lower rate of clinically important GI catastrophes such as haemorrhage, perforation, obstruction than conventional NSAIDs. They also have their own spectrum of side-effects and, it is important to note, that their efficacy in palliating OA pain is no greater than existing NSAIDs."

References

1. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995; 38: 1535-1540.

2. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995; 38: 1541-1546.
-end-
Press contact:
Claire Powell
MediTech Media
Tel: 44-0-171-404-7151 ext 172
Fax: 44-0-171-404-6946
email: ClaireP@meditech.co.uk

MediTech Media Ltd.

Related Osteoarthritis Articles from Brightsurf:

Major savings possible with app-based osteoarthritis treatment
Osteoarthritis treatment conducted digitally via an app costs around 25% of what conventional care costs, according to a study from Lund University in Sweden published in the research journal PLOS ONE.

New approach to treating osteoarthritis advances
Injections of a natural 'energy' molecule prompted regrowth of almost half of the cartilage lost with aging in knees, a new study in rodents shows.

Bone drug may be beneficial for knee osteoarthritis
Bisphosphonates (a class of drugs that prevent the loss of bone density and used to treat osteoporosis and similar diseases) appear to be safe and beneficial for osteoarthritis patients.

Certain jobs linked to higher risk of knee osteoarthritis
Workers in jobs that typically involve heavy lifting, frequent climbing, prolonged kneeling, squatting, and standing face an increased risk of developing knee osteoarthritis.

App helps reduce osteoarthritis pain
By performing a few simple physical exercises daily, and receiving information about their disease regularly, 500 osteoarthritis patients were able to on average halve their pain in 6 months -- and improve their physical function.

Osteoarthritis can increase your risk for social isolation
In a study published in the Journal of the American Geriatrics Society, researchers examined information from the European Project on OSteoArthritis (EPOSA) study.

High rates of opioid prescriptions for osteoarthritis
Opioids work against severe pain but the risks of side effects and addiction are high.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

3D printing may help treat osteoarthritis
In a Journal of Orthopaedic Research study, scientists used 3D printing to repair bone in the joints of mini-pigs, an advance that may help to treat osteoarthritis in humans.

Finger joint enlargements may be linked to knee osteoarthritis
Heberden's nodes (HNs) are bony enlargements of the finger joints that are readily detectable in a routine physical exam and are considered hallmarks of osteoarthritis.

Read More: Osteoarthritis News and Osteoarthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.